New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
10:08 EDTCVSCVS Caremark sees 2014 share repurchases of $4B
CVS says that it is "well-positioned" for growth in a changing health care landscape. Says increased Medicaid enrollment will fuel its leading position in managed Medicaid. Sees 43M people enrolled in Medicaid enrollment by 2016. Says "well-positioned" to gain share in exchanges across the enterprise. Says overall growth in exchanges will be a net positive. Says focused on enhancing shareholder value through driving long-term growth, generating "significant" free cash flow and optimizing capital allocation. In terms of CAGR from FY13-FY18, CVS sees net revenue 9%-13%, sees operating profit 7%-9%, sees final adjusted EPS 10%-14%, sees share repurchase contribution 4%-6% and average annual cash available for enhancing shareholder value $7.5B-$8.5B. When discussing efficient cash deployment from FY14 through FY18, CVS says it will have $40B in cash available for enhancing shareholder value. Expects a target payout ratio for dividends during that time to be 35% by FY18 with 18% implied dividend CAGR. Expects a return on invested capital and says that it will drive ROIC with value-enhancing projects. Sees $4B-$5B of share repurchases per year through 2018. Comments taken from slides from CVS Caremark's presentation at the Wells Fargo Healthcare conference.
News For CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
14:53 EDTCVSCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use